In response to inquiries from the news media about the ASTEROID trial for Crestor presented today at the American College of Cardiology, Pfizer issued the following statement:

-- Only Lipitor has demonstrated significant LDL reductions and cardiovascular benefits for a wide range of patients, with an excellent efficacy and safety profile across the full dose range.

-- This is not the first time a statin has demonstrated plaque regression. The REVERSAL trial compared treatment with Lipitor 80mg to another lipid lowering agent over 18 months. In a subset of high-plaque burden patients, Lipitor demonstrated a 5.9% (P